EW - Edwards Lifesciences Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
130.62
+1.10 (+0.85%)
As of 12:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close129.52
Open129.51
Bid130.39 x 100
Ask130.43 x 200
Day's Range127.45 - 130.91
52 Week Range97.70 - 143.22
Volume892,253
Avg. Volume1,370,648
Market Cap27.498B
Beta0.68
PE Ratio (TTM)48.38
EPS (TTM)2.70
Earnings DateApr 23, 2018 - Apr 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est146.37
Trade prices are not sourced from all markets
  • Edward Life Sciences drops on mixed earnings release
    CNBC Videos2 days ago

    Edward Life Sciences drops on mixed earnings release

    CNBC's Kate Rogers reports on the quarterly earnings for Edward Life Sciences.

  • Thomson Reuters StreetEvents19 hours ago

    Edited Transcript of EW earnings conference call or presentation 24-Apr-18 9:00pm GMT

    Q1 2018 Edwards Lifesciences Corp Earnings Call

  • Associated Press20 hours ago

    Edwards Lifesciences, General Dynamics slip; Comcast rises

    Stocks that moved substantially or traded heavily Wednesday: Comcast Corp., up 91 cents to $34.26 The cable company had a solid first quarter and offered to buy U.K. broadcaster Sky for $30 billion. Texas ...

  • Edwards CEO Mike Mussallem Driven By Passion For Helping Others
    Investor's Business Daily20 hours ago

    Edwards CEO Mike Mussallem Driven By Passion For Helping Others

    Motivated by a goal to create meaning in his work, Edwards Lifesciences[ticker symb=EW] CEO Mike Mussallem pushed boundaries to follow his passion for helping people live their best lives. In the process, Mussallem and his team have transformed Edwards into the global leader in patient-focused innovations for structural heart disease, as well as critical care and surgical monitoring. Mussallem believes...

  • Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
    Zacksyesterday

    Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss

    Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.

  • Premarket: Futures Improve As Boeing, Twitter, 3 Chip Stocks Soar
    Investor's Business Dailyyesterday

    Premarket: Futures Improve As Boeing, Twitter, 3 Chip Stocks Soar

    Premarket trading turned mixed on Wednesday as Boeing, Twitter and Cree gained, Alphabet got an upgrade and Comcast bid $31 billion for Britain's Sky.

  • What Drove Edwards Lifesciences’ 1Q18 Earnings?
    Market Realistyesterday

    What Drove Edwards Lifesciences’ 1Q18 Earnings?

    Japan is the company’s highest growth region outside the United States. Therapy adoption continues to be the major factor driving Edwards’ THVT segment sales in 1Q18. For more on related developments, read Recent Developments at Edwards Lifesciences.

  • Edwards Lifesciences Missed Sales Estimates in 1Q18
    Market Realistyesterday

    Edwards Lifesciences Missed Sales Estimates in 1Q18

    Edwards Lifesciences Stock Fell on Missed 1Q18 Sales EstimatesEdwards Lifesciences releases 1Q18 results

  • InvestorPlaceyesterday

    3 Stocks to Watch on Wednesday: Edwards Lifesciences Corp (EW), Illumina, Inc. (ILMN) and Tesla Inc (TSLA)

    Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.

  • Reuters2 days ago

    Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

    Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc. The company's shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver. "Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor," Chief Executive Officer Michael A. Mussallem said on a call with analysts.

  • MarketWatch2 days ago

    Edwards Lifesciences stock drops 8% after forecast misses

    Edwards Lifesciences Corp. shares dropped in late trading Tuesday after the company provided a disappointing forecast. The company reported first-quarter earnings of 96 cents a share on sales of $894.8 ...

  • Despite Today's Market, Baozun And Solaredge Technologies Join Sector Leaders
    Investor's Business Daily2 days ago

    Despite Today's Market, Baozun And Solaredge Technologies Join Sector Leaders

    Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.

  • Edwards Lifesciences Tanks After Heart-Valve Sales Lag Expectations
    Investor's Business Daily2 days ago

    Edwards Lifesciences Tanks After Heart-Valve Sales Lag Expectations

    For the first quarter, Edwards reported $937.5 million in adjusted sales and adjusted profit of $1.22 per share.

  • CNBC2 days ago

    After-hours buzz: TXN, WYNN, EW & more

    See which stocks are posting big moves after the bell.

  • The Hottest Earnings Charts This Week
    Zacks2 days ago

    The Hottest Earnings Charts This Week

    All eyes will be on these hot stocks during this busy earnings week.

  • Associated Press2 days ago

    Edwards Lifesciences: 1Q Earnings Snapshot

    On a per-share basis, the Irvine, California-based company said it had net income of 96 cents. Earnings, adjusted for non-recurring costs, were $1.22 per share. The results beat Wall Street expectations. ...

  • Reuters2 days ago

    Edwards Lifesciences reports 1.3 pct rise in quarterly sales

    Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business. The company's net profit ...

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire2 days ago

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • ACCESSWIRE2 days ago

    Edwards Lifesciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Edwards Lifesciences Corporation (NYSE: EW ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern ...

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist2 days ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Will Boston Scientific Beat 1Q18 Earnings Estimates?
    Market Realist2 days ago

    Will Boston Scientific Beat 1Q18 Earnings Estimates?

    In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.

  • Boston Scientific’s 1Q18 Revenues: What to Expect
    Market Realist3 days ago

    Boston Scientific’s 1Q18 Revenues: What to Expect

    On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.

  • What to Expect from Edward Lifesciences’ 1Q18 Earnings
    Market Realist3 days ago

    What to Expect from Edward Lifesciences’ 1Q18 Earnings

    Edwards Lifesciences (EW) will announce its 1Q18 earnings results for the quarter ended March 31, 2018, on April 24. The company is a leader in the TAVR (transcatheter aortic valve replacement) market space and manufactures the market-leading Sapien family of valves. The company reported robust 4Q17 and fiscal 2017 results on February 1, 2018, which triggered a 7% of stock price rise.

  • Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings
    Market Realist3 days ago

    Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings

    The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.

  • Why Earnings Season Could Be Great for Edwards Lifesciences (EW)
    Zacks3 days ago

    Why Earnings Season Could Be Great for Edwards Lifesciences (EW)

    Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.